Table 2.
Characteristics of the identified studies
| Ref. | Age median, yr (range) | Sex m/tot n (%) | hENT1 method | Chemotherapy | Radiation dose Gy/(Gy/frac) | Outcome measurement | Quality REMARK |
| Spratlin et al[9] | 58 (51-64)1 | 11 (52) | IHC | Pall Gem | No | OS | 10 |
| Giovannetti et al[10] | 65 (22-83) | 53 (50) | RT-PCR | Pall Gem Adj Gem | 45 | OS, DFS, TTP, RR | 12 |
| Farrell et al[12] | 53/63/652 | 45 (49) | IHC | Adj Gem | 50.4 | OS, DFS, Tox | 17 |
| Maréchal et al[3] | 56 (34-83) | 23 (51) | IHC | Adj Gem | 40-50.4 | OS, DFS, Tox | 13 |
| Fujita et al[8] | 65 (36-86) | 42 (60) | RT-PCR | Adj Gem or Resection only | No | OS, DFS | 12 |
| Maréchal et al[1] | NR | 129 (53) | IHC | Adj Gem | 50.4 | OS | 15 |
| Kawada et al[2] | - (41-81) | 33 (52) | IHC | Neo Gem Adj 5-FU | 50/2 | DSS | 9 |
| Morinaga et al[21] | 64 (45-74) | 17 (63) | IHC | Adj Gem | No | OS, DFS | 12 |
| Murata et al[22] | 68 (44-87) | 38 (69) | IHC | Neo Gem Adj Gem | 45/2 | OS, DFS, RR | 13 |
| Nakagawa et al[23] | 67 (41-83) | 52 (48) | IHC | Adj Gem + S1 | No | OS, DFS | 13 |
1
95%CI;
2
Medians in the different hENT1 expression groups. IHC: Immunohistochemistry; RT-PCR: Reverse transcription polymerase chain reaction; Adj: Adjuvant; Neo: Neoadjuvant; Radio: Radiotherapy; Gem: Gemcitabine; Pall: Palliative; OS: Overall survival; DFS: Disease-free survival; Tox: Toxicity; TTP: Time to progression; DSS: Disease-specific survival; RR: Response rate.